microtubule assembly Search Results


microtubule assembly  (Chemie GmbH)
90
Chemie GmbH microtubule assembly
Microtubule Assembly, supplied by Chemie GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microtubule+assembly/microtubule+assembly/10__1002_slash_anie__201913001-47-96-119
Average 90 stars, based on 1 article reviews
microtubule assembly - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
microtubule assembly and  (Neurogeneration)
90
Neurogeneration microtubule assembly and
Microtubule Assembly And, supplied by Neurogeneration, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microtubule+assembly/microtubule+assembly+and/pmc03533556-334-17-20
Average 90 stars, based on 1 article reviews
microtubule assembly and - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
microtubule assembly inhibitor (vinblastine)  (CEM Corporation)
90
CEM Corporation microtubule assembly inhibitor (vinblastine)
miR-135b and miR-196b are upregulated in response to DNA damaging drugs in a time- and dose-dependent manner in CCRF-CEM cells. (A) miR-135b and -196b expression began to increase after 24 h exposure to 300 nM of etoposide, a DNA damaging agent (IC50: 300 nM). (B) In contrast, no substantial increase in miR-135b and -196b expression in cells treated with 4 nM of <t>vinblastine,</t> a <t>microtubule</t> assembly inhibitor (IC50: 4 nM). CCRF-CEM cells were then exposed to DNA damaging agents (etoposide, topotecan, and doxorubicin) or non-DNA damaging agents (vinblastine and paclitaxel) at the indicated concentrations. Expressions of miR-135b and miR-196b increased in a dose-dependent fashion after treatment of cells with (C) etoposide (IC50: 300 nM), (D) topotecan (IC50: 15 nM), and (E) doxorubicin (IC50: 150 nM) at different concentrations. In contrast, no significant changes were seen when CCRF-CEM cells were treated with (F) vinblastine (IC50: 4 nM) or (G) paclitaxel (IC50: 3 nM). Total RNA was collected after 48 hr of drug incubation. Values are mean ± SE (n = 3). *, p < 0.05.
Microtubule Assembly Inhibitor (Vinblastine), supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microtubule+assembly/microtubule+assembly+inhibitor++vinblastine+/pmc04981649-242-14-8
Average 90 stars, based on 1 article reviews
microtubule assembly inhibitor (vinblastine) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
microtubule assembly  (The Company of Biologists)
90
The Company of Biologists microtubule assembly
miR-135b and miR-196b are upregulated in response to DNA damaging drugs in a time- and dose-dependent manner in CCRF-CEM cells. (A) miR-135b and -196b expression began to increase after 24 h exposure to 300 nM of etoposide, a DNA damaging agent (IC50: 300 nM). (B) In contrast, no substantial increase in miR-135b and -196b expression in cells treated with 4 nM of <t>vinblastine,</t> a <t>microtubule</t> assembly inhibitor (IC50: 4 nM). CCRF-CEM cells were then exposed to DNA damaging agents (etoposide, topotecan, and doxorubicin) or non-DNA damaging agents (vinblastine and paclitaxel) at the indicated concentrations. Expressions of miR-135b and miR-196b increased in a dose-dependent fashion after treatment of cells with (C) etoposide (IC50: 300 nM), (D) topotecan (IC50: 15 nM), and (E) doxorubicin (IC50: 150 nM) at different concentrations. In contrast, no significant changes were seen when CCRF-CEM cells were treated with (F) vinblastine (IC50: 4 nM) or (G) paclitaxel (IC50: 3 nM). Total RNA was collected after 48 hr of drug incubation. Values are mean ± SE (n = 3). *, p < 0.05.
Microtubule Assembly, supplied by The Company of Biologists, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microtubule+assembly/microtubule+assembly/pm08175915-13-15-12
Average 90 stars, based on 1 article reviews
microtubule assembly - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
colchicine/gadolinium-loaded microtubule protein self-assembled  (NanoCarrier Co)
90
NanoCarrier Co colchicine/gadolinium-loaded microtubule protein self-assembled
miR-135b and miR-196b are upregulated in response to DNA damaging drugs in a time- and dose-dependent manner in CCRF-CEM cells. (A) miR-135b and -196b expression began to increase after 24 h exposure to 300 nM of etoposide, a DNA damaging agent (IC50: 300 nM). (B) In contrast, no substantial increase in miR-135b and -196b expression in cells treated with 4 nM of <t>vinblastine,</t> a <t>microtubule</t> assembly inhibitor (IC50: 4 nM). CCRF-CEM cells were then exposed to DNA damaging agents (etoposide, topotecan, and doxorubicin) or non-DNA damaging agents (vinblastine and paclitaxel) at the indicated concentrations. Expressions of miR-135b and miR-196b increased in a dose-dependent fashion after treatment of cells with (C) etoposide (IC50: 300 nM), (D) topotecan (IC50: 15 nM), and (E) doxorubicin (IC50: 150 nM) at different concentrations. In contrast, no significant changes were seen when CCRF-CEM cells were treated with (F) vinblastine (IC50: 4 nM) or (G) paclitaxel (IC50: 3 nM). Total RNA was collected after 48 hr of drug incubation. Values are mean ± SE (n = 3). *, p < 0.05.
Colchicine/Gadolinium Loaded Microtubule Protein Self Assembled, supplied by NanoCarrier Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microtubule+assembly/colchicine+gadolinium+loaded+microtubule+protein+self+assembled/10__1016_slash_j__cej__2023__148472-231-3-7
Average 90 stars, based on 1 article reviews
colchicine/gadolinium-loaded microtubule protein self-assembled - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
microtubule dynamics and assembly  (Funakoshi ltd)
90
Funakoshi ltd microtubule dynamics and assembly
miR-135b and miR-196b are upregulated in response to DNA damaging drugs in a time- and dose-dependent manner in CCRF-CEM cells. (A) miR-135b and -196b expression began to increase after 24 h exposure to 300 nM of etoposide, a DNA damaging agent (IC50: 300 nM). (B) In contrast, no substantial increase in miR-135b and -196b expression in cells treated with 4 nM of <t>vinblastine,</t> a <t>microtubule</t> assembly inhibitor (IC50: 4 nM). CCRF-CEM cells were then exposed to DNA damaging agents (etoposide, topotecan, and doxorubicin) or non-DNA damaging agents (vinblastine and paclitaxel) at the indicated concentrations. Expressions of miR-135b and miR-196b increased in a dose-dependent fashion after treatment of cells with (C) etoposide (IC50: 300 nM), (D) topotecan (IC50: 15 nM), and (E) doxorubicin (IC50: 150 nM) at different concentrations. In contrast, no significant changes were seen when CCRF-CEM cells were treated with (F) vinblastine (IC50: 4 nM) or (G) paclitaxel (IC50: 3 nM). Total RNA was collected after 48 hr of drug incubation. Values are mean ± SE (n = 3). *, p < 0.05.
Microtubule Dynamics And Assembly, supplied by Funakoshi ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microtubule+assembly/microtubule+dynamics+and+assembly/10__1091_slash_mbc__5__suppl__383a-1697-3-19
Average 90 stars, based on 1 article reviews
microtubule dynamics and assembly - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
pick-and-place assembly of single microtubules  (Verlag GmbH)
90
Verlag GmbH pick-and-place assembly of single microtubules
miR-135b and miR-196b are upregulated in response to DNA damaging drugs in a time- and dose-dependent manner in CCRF-CEM cells. (A) miR-135b and -196b expression began to increase after 24 h exposure to 300 nM of etoposide, a DNA damaging agent (IC50: 300 nM). (B) In contrast, no substantial increase in miR-135b and -196b expression in cells treated with 4 nM of <t>vinblastine,</t> a <t>microtubule</t> assembly inhibitor (IC50: 4 nM). CCRF-CEM cells were then exposed to DNA damaging agents (etoposide, topotecan, and doxorubicin) or non-DNA damaging agents (vinblastine and paclitaxel) at the indicated concentrations. Expressions of miR-135b and miR-196b increased in a dose-dependent fashion after treatment of cells with (C) etoposide (IC50: 300 nM), (D) topotecan (IC50: 15 nM), and (E) doxorubicin (IC50: 150 nM) at different concentrations. In contrast, no significant changes were seen when CCRF-CEM cells were treated with (F) vinblastine (IC50: 4 nM) or (G) paclitaxel (IC50: 3 nM). Total RNA was collected after 48 hr of drug incubation. Values are mean ± SE (n = 3). *, p < 0.05.
Pick And Place Assembly Of Single Microtubules, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microtubule+assembly/pick+and+place+assembly+of+single+microtubules/pm28692749-18-16-6
Average 90 stars, based on 1 article reviews
pick-and-place assembly of single microtubules - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
microtubule assembly  (Federation of European Neuroscience Societies)
90
Federation of European Neuroscience Societies microtubule assembly
miR-135b and miR-196b are upregulated in response to DNA damaging drugs in a time- and dose-dependent manner in CCRF-CEM cells. (A) miR-135b and -196b expression began to increase after 24 h exposure to 300 nM of etoposide, a DNA damaging agent (IC50: 300 nM). (B) In contrast, no substantial increase in miR-135b and -196b expression in cells treated with 4 nM of <t>vinblastine,</t> a <t>microtubule</t> assembly inhibitor (IC50: 4 nM). CCRF-CEM cells were then exposed to DNA damaging agents (etoposide, topotecan, and doxorubicin) or non-DNA damaging agents (vinblastine and paclitaxel) at the indicated concentrations. Expressions of miR-135b and miR-196b increased in a dose-dependent fashion after treatment of cells with (C) etoposide (IC50: 300 nM), (D) topotecan (IC50: 15 nM), and (E) doxorubicin (IC50: 150 nM) at different concentrations. In contrast, no significant changes were seen when CCRF-CEM cells were treated with (F) vinblastine (IC50: 4 nM) or (G) paclitaxel (IC50: 3 nM). Total RNA was collected after 48 hr of drug incubation. Values are mean ± SE (n = 3). *, p < 0.05.
Microtubule Assembly, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microtubule+assembly/microtubule+assembly/pm06852237-26-3-29
Average 90 stars, based on 1 article reviews
microtubule assembly - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


miR-135b and miR-196b are upregulated in response to DNA damaging drugs in a time- and dose-dependent manner in CCRF-CEM cells. (A) miR-135b and -196b expression began to increase after 24 h exposure to 300 nM of etoposide, a DNA damaging agent (IC50: 300 nM). (B) In contrast, no substantial increase in miR-135b and -196b expression in cells treated with 4 nM of vinblastine, a microtubule assembly inhibitor (IC50: 4 nM). CCRF-CEM cells were then exposed to DNA damaging agents (etoposide, topotecan, and doxorubicin) or non-DNA damaging agents (vinblastine and paclitaxel) at the indicated concentrations. Expressions of miR-135b and miR-196b increased in a dose-dependent fashion after treatment of cells with (C) etoposide (IC50: 300 nM), (D) topotecan (IC50: 15 nM), and (E) doxorubicin (IC50: 150 nM) at different concentrations. In contrast, no significant changes were seen when CCRF-CEM cells were treated with (F) vinblastine (IC50: 4 nM) or (G) paclitaxel (IC50: 3 nM). Total RNA was collected after 48 hr of drug incubation. Values are mean ± SE (n = 3). *, p < 0.05.

Journal: International Journal of Biochemistry and Molecular Biology

Article Title: Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines

doi:

Figure Lengend Snippet: miR-135b and miR-196b are upregulated in response to DNA damaging drugs in a time- and dose-dependent manner in CCRF-CEM cells. (A) miR-135b and -196b expression began to increase after 24 h exposure to 300 nM of etoposide, a DNA damaging agent (IC50: 300 nM). (B) In contrast, no substantial increase in miR-135b and -196b expression in cells treated with 4 nM of vinblastine, a microtubule assembly inhibitor (IC50: 4 nM). CCRF-CEM cells were then exposed to DNA damaging agents (etoposide, topotecan, and doxorubicin) or non-DNA damaging agents (vinblastine and paclitaxel) at the indicated concentrations. Expressions of miR-135b and miR-196b increased in a dose-dependent fashion after treatment of cells with (C) etoposide (IC50: 300 nM), (D) topotecan (IC50: 15 nM), and (E) doxorubicin (IC50: 150 nM) at different concentrations. In contrast, no significant changes were seen when CCRF-CEM cells were treated with (F) vinblastine (IC50: 4 nM) or (G) paclitaxel (IC50: 3 nM). Total RNA was collected after 48 hr of drug incubation. Values are mean ± SE (n = 3). *, p < 0.05.

Article Snippet: In contrast, no significant changes were seen when CCRF-CEM cells were treated with a microtubule assembly inhibitor (vinblastine) ( ) or a microtubule stabilizer (paclitaxel) , further implying that the induction of miR-135b and miR-196b may be a consequence of DNA damage. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 3 caption a7 miR-135b and miR-196b are upregulated in response to DNA damaging drugs in a time- and dose-dependent manner in CCRF-CEM cells. (A) miR-135b and -196b expression began to increase after 24 h exposure to 300 nM of etoposide, a DNA damaging agent (IC 50 : 300 nM). (B) In contrast, no substantial increase in miR-135b and -196b expression in cells treated with 4 nM of vinblastine, a microtubule assembly inhibitor (IC 50 : 4 nM).

Techniques: Expressing, Incubation